Negative in Ames, in vitro chromosomal aberration, in vitro TK6 micronucleus and in vivo rat micronucleus assays
“Leniolisib was not genotoxic in the in vitro Ames assay, in vitro chromosomal aberration assay in human lymphocytes, or micronucleus assays in TK6 cells ( in vitro ) and rats ( in vivo ).”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: embryofetal toxicity including malformations at 2-6x MRHD (AUC)
“In animal reproduction studies, oral administration of leniolisib to pregnant rats and rabbits during the period of organogenesis at exposures approximately 2-6 times the MRHD on an AUC basis, produced embryofetal toxicity including malformations ( see Data ).”
hERG IC50 11.9 μM; QTc prolongation in two monkey telemetry studies at 150 mg/kg
“Leniolisib was found to inhibit hERG channel currents in hERG-transfected HEK cells with an IC50 of 11.9 μM. Consistent with this finding, single dose leniolisib (150 mg/kg, oral) administration induced QTcI (QT interval, individual correction) prolongation in two separate monkey telemetry studies.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Genotox: Ames
Negative up to 5,000 μg/plate
“In the bacterial reverse mutation assay, there was no evidence of mutagenicity of leniolisib at up to 5,000 μg/plate.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Genotox: in vitro mammalian
Chromosomal aberration (human lymphocytes) and TK6 micronucleus: negative
“Leniolisib was not genotoxic in the in vitro Ames assay, in vitro chromosomal aberration assay in human lymphocytes, or micronucleus assays in TK6 cells ( in vitro ) and rats ( in vivo ).”
“In an in vivo micronucleus assay with rats, there were no statistically significant effects of leniolisib treatment on the number of micronucleated polychromatic erythrocytes at doses up to 700 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity model
6-month Tg.rasH2 mouse: not carcinogenic up to 80 mg/kg/day
“Leniolisib was not carcinogenic in the 6-month carcinogenicity study in Tg.rasH2 transgenic mice at doses up to 80 mg/kg/day.”
6-month Tg-rasH2 mouse and 2-year rat studies ongoing at approval; final reports due as postmarketing requirements
“The 6-month transgenic (Tg-RasH2) mouse carcinogenicity study and 2-year carcinogenicity study with rats are ongoing under Special Protocol Assessments with ECAC concurrence. The final study reports will be submitted as post-marketing requirements.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
hERG / QT
hERG IC50 11.9 μM; QTcI prolongation in two monkey telemetry studies at 150 mg/kg
“Leniolisib was found to inhibit hERG channel currents in hERG-transfected HEK cells with an IC50 of 11.9 μM. Consistent with this finding, single dose leniolisib (150 mg/kg, oral) administration induced QTcI (QT interval, individual correction) prolongation in two separate monkey telemetry studies.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative